BACKGROUND: Plasma exchange (PEX) treatment for patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) has risk for major complications. STUDY DESIGN AND METHODS: Data for PEX-related complications have been prospectively collected on all patients enrolled in the Oklahoma TTP-HUS Registry, 1996 to 2011. PEX-related complications have been defined as major or minor and as central venous catheter related or plasma related. RESULTS: During 15 years, 1996 to 2011, 72 (24%) of 302 consecutive patients had major PEX-related complications. Analysis of five consecutive 3-year cohorts demonstrated that there has been a significant trend for decreasing frequency of all PEX-related major complications (p = 0.014) and central venous catheter-related major complications (p = 0.021) but not for the less common plasma-related major complications (p = 0.380). ADAMTS13 activity was measured in 288 (95%) of the 302 patients. Analysis of the 66 patients with ADAMTS13 activity of less than 10% demonstrated a significant trend for decreasing frequency of PEX-related major complications (p = 0.036); the trend for the 222 patients with ADAMTS13 activity of at least 10% was not significant (p = 0.118). The decreased frequency of PEX-related major complications among patients with ADAMTS13 activity of less than 10% may be related to a significant trend for decreasing duration of PEX treatment (p = 0.040) and decreasing frequency of requirement for more than one central venous catheter (p = 0.044). The decreased duration of PEX treatment may be related to increased use of adjunctive treatments: corticosteroids (p < 0.001) and rituximab (p < 0.001). CONCLUSIONS: The frequency of PEX-related major complications has decreased from 1996 to 2011, possibly related to increased use of corticosteroids and rituximab and the decreased duration of PEX required to achieve remission.
BACKGROUND: Plasma exchange (PEX) treatment for patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) has risk for major complications. STUDY DESIGN AND METHODS: Data for PEX-related complications have been prospectively collected on all patients enrolled in the Oklahoma TTP-HUS Registry, 1996 to 2011. PEX-related complications have been defined as major or minor and as central venous catheter related or plasma related. RESULTS: During 15 years, 1996 to 2011, 72 (24%) of 302 consecutive patients had major PEX-related complications. Analysis of five consecutive 3-year cohorts demonstrated that there has been a significant trend for decreasing frequency of all PEX-related major complications (p = 0.014) and central venous catheter-related major complications (p = 0.021) but not for the less common plasma-related major complications (p = 0.380). ADAMTS13 activity was measured in 288 (95%) of the 302 patients. Analysis of the 66 patients with ADAMTS13 activity of less than 10% demonstrated a significant trend for decreasing frequency of PEX-related major complications (p = 0.036); the trend for the 222 patients with ADAMTS13 activity of at least 10% was not significant (p = 0.118). The decreased frequency of PEX-related major complications among patients with ADAMTS13 activity of less than 10% may be related to a significant trend for decreasing duration of PEX treatment (p = 0.040) and decreasing frequency of requirement for more than one central venous catheter (p = 0.044). The decreased duration of PEX treatment may be related to increased use of adjunctive treatments: corticosteroids (p < 0.001) and rituximab (p < 0.001). CONCLUSIONS: The frequency of PEX-related major complications has decreased from 1996 to 2011, possibly related to increased use of corticosteroids and rituximab and the decreased duration of PEX required to achieve remission.
Authors: J R McMinn; Ira A Thomas; Deirdra R Terrell; Deanna Duvall; Sara K Vesely; James N George Journal: Transfusion Date: 2003-03 Impact factor: 3.157
Authors: Johanna A Kremer Hovinga; Sara K Vesely; Deirdra R Terrell; Bernhard Lämmle; James N George Journal: Blood Date: 2009-12-23 Impact factor: 22.113
Authors: Marijn Hameeteman; Aron S Bode; Arnoud G Peppelenbosch; Frank M van der Sande; Jan H M Tordoir Journal: J Vasc Access Date: 2010 Oct-Dec Impact factor: 2.283
Authors: Andrew G Longmate; Kirsteen S Ellis; Louise Boyle; Shaun Maher; Chris J S Cairns; Suzanne M Lloyd; Colin Lang Journal: BMJ Qual Saf Date: 2011-02 Impact factor: 7.035
Authors: Curt D Froehlich; Mark R Rigby; Eli S Rosenberg; Ruosha Li; Pei-Ling J Roerig; Kirk A Easley; Jana A Stockwell Journal: Crit Care Med Date: 2009-03 Impact factor: 7.598
Authors: Chong H Kim; Sierra C Simmons; Lance A Williams; Elizabeth M Staley; X Long Zheng; Huy P Pham Journal: Transfusion Date: 2017-06-23 Impact factor: 3.157
Authors: Elie Azoulay; Philippe R Bauer; Eric Mariotte; Lene Russell; Paul Knoebl; Ignacio Martin-Loeches; Frédéric Pène; Kathryn Puxty; Pedro Povoa; Andreas Barratt-Due; Jose Garnacho-Montero; Julia Wendon; Laveena Munshi; Dominique Benoit; Michael von Bergwelt-Baildon; Marco Maggiorini; Paul Coppo; Spero Cataland; Agnès Veyradier; Andry Van de Louw Journal: Intensive Care Med Date: 2019-10-07 Impact factor: 17.440